Skip to main content Back to Top
Advertisement

3/20/2020

Benztropine Mesylate Injection

Products Affected - Description

    • Cogentin injection, Akorn, 1 mg/mL, 2 mL ampule, 5 count, NDC 76478-0611-02
    • Benztropine Mesylate injection, Akorn, 1 mg/mL, 2 mL ampule, 5 count, NDC 17478-0012-02
    • Benztropine Mesylate injection, Fresenius Kabi, 1 mg/mL, 2 mL vial, 5 count, NDC 63323-0970-02

Reason for the Shortage

    • Akorn is not marketing benztropine 1 mg/mL 2 mL ampules and Cogentin 1 mg/mL 2 mL ampules.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.

Available Products

    • Benztropine Mesylate injection, Hikma, 1 mg/mL, 2 mL ampule, 5 count, NDC 00143-9729-05

Estimated Resupply Dates

    • Fresenius Kabi has short-dated benztropine 1 mg/mL 2 mL vials available with an expiration date of <9 months.

Updated

Updated March 20, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 30, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.